Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VRX-496(VIRxSYS).

Kevin V Morris1

  • 1Division of Molecular Medicine, Beckman Research Institute at the City of Hope, 1450 East Duarte Road, Duarte, CA 91010-3011, USA. kmorris@coh.org

Current Opinion in Investigational Drugs (London, England : 2000)
|March 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation.

Drug delivery and translational research·2025
Same author

Genetic protection from type 1 diabetes resulting from accelerated insulin mRNA decay.

Cell·2025
Same author

Current State of Therapeutics for HTLV-1.

Viruses·2024
Same author

Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Nucleic acid therapeutics·2024
Same author

Therapeutic potential of RNA-enriched extracellular vesicles: The next generation in RNA delivery via biogenic nanoparticles.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.

Antiviral research·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

VIRxSYS is developing VRX-496, a gene therapy using lentiviral vectors to combat HIV infection. The first patient received a dose in a Phase I/IIa clinical trial in July 2003.

Area of Science:

  • Gene therapy
  • Virology
  • Immunology

Background:

  • Human Immunodeficiency Virus (HIV) remains a significant global health challenge.
  • Current treatments for HIV infection involve lifelong antiretroviral therapy.
  • Novel therapeutic strategies, including gene therapy, are being explored to provide a functional cure for HIV.

Purpose of the Study:

  • To evaluate the safety and potential efficacy of VRX-496, a novel gene therapy for HIV infection.
  • To assess the feasibility of using lentiviral vectors for delivering anti-HIV genetic material.
  • To initiate a Phase I/IIa clinical trial for VRX-496 in HIV-positive patients.

Main Methods:

  • Development of VRX-496, a lentiviral vector encoding anti-HIV antisense envelope sequences.

Related Experiment Videos

  • Initiation of a Phase I/IIa clinical trial involving the initial dosing of an HIV-positive patient.
  • Monitoring of patient safety and preliminary efficacy indicators post-dosing.

    • Main Results:

    • The initial dosing of an HIV-positive patient with VRX-496 was successfully undertaken in July 2003.
    • Preliminary safety data from the first patient are expected to be reported.
    • Further results regarding viral load and immune response will be assessed as the trial progresses.

    Conclusions:

    • VRX-496 represents a potential new gene therapy approach for managing HIV infection.
    • The initiation of this clinical trial marks a step forward in exploring lentiviral vector-based therapies for HIV.
    • Ongoing research and clinical trials are crucial for determining the long-term viability of VRX-496.